Chanson International Holding Deepens Tourism Market Footprint with New Stores in Urumqi Grand Bazaar and Kashgar Old City

Bitdeer Technologies Group (BTDR) said its Tydal Data Center subsidiary in Norway signed a 16-year colocation lease and services deal with Volta Tydal AS for 121 MW and about $4.70 billion in contracted revenue, with an 8-year renewal option that could raise total value to about $8.0 billion. The campus is renewable-powered, set for NVIDIA GPU clusters, and includes $1.30 billion in credit support.

Core Scientific (CORZ) said it signed a 15-year infrastructure partnership with AMD (AMD) for data-center power starting in 2027. The deal covers about 530 MW across five sites, with AMD leasing 377 MW and a neocloud leasing 152 MW. Core Scientific said it has $14B+ potential base contracted revenue. The news follows shareholders rejecting a CoreWeave all-stock deal valued around $9B.

Reuters explains the U.S. Patriot mobile air defense system, built by Raytheon Technologies, and its PAC-2 and PAC-3 interceptor variants. Demand has risen as Russia’s strikes in Ukraine and the Middle East conflict have depleted interceptor stocks. CSIS estimates about 65% of U.S. interceptors were used Feb-July, leaving under 850. Lockheed received a contract up to $58.6B.

UnitedHealth Group (UNH) said it will commit $4 million via the United Health Foundation to expand the University of Tennessee Health Sciences health hub network from 5 to 13 sites by end-2027, reaching about 200,000 residents. The company reported Q2 revenue of $112B and adjusted EPS of $6.38, raised full-year adjusted EPS guidance to $19.50-$20.

The Wall Street Journal reported Apple is testing memory chips from China’s CXMT across iPhones and MacBooks and has held early talks to supply components for some China-sold devices. Apple is seeking White House approval amid “unsustainable” pricing from SK Hynix, Samsung, Micron and SanDisk. US rules limit customization, but off-the-shelf purchases may be allowed.

AstraZeneca and CSPC Pharmaceutical Group signed a contract to form a joint venture to build a new-generation biologics manufacturing facility in Shijiazhuang, China. The JV will be capitalized 51% by CSPC and 49% by AstraZeneca, subject to regulatory approvals. It will initially make and supply biologics drug substances for global markets.